CURE’s mesothelioma page is a go-to resource for oncology news and updates in the world of mesothelioma Here, readers will find cancer articles, videos, podcasts, and more with expert insight to the latest treatments and research in mesothelioma.
November 21st 2023, 4:00pm
The Keytruda-Lenvima combination had promising anti-tumor activity for patients with pleural mesothelioma following disease progression after chemotherapy.
November 14th 2023, 6:00pm
Here are ways to become a patient advocate.
October 26th 2023, 5:00pm
I had the wrong interpretation of what a cancer survivor was. That was until I was diagnosed with a rare cancer and shockingly, the term “cancer survivor” became a part of my journey.
September 8th 2023, 5:00pm
After getting over the shock of being diagnosed with a rare cancer, I could only think about returning to my “normal” self, but I later discovered that the normal I was trying to return to would change.
August 7th 2023, 5:00pm
I’ve heard of many stories of friendships dwindling after someone has been diagnosed with cancer. One thing about it is that I can relate.
May 20th 2023, 6:00pm
After being diagnosed with a rare form of cancer — and seeing a clinician who did not know how to treat me — I learned the importance of asking questions to my providers and advocating for myself
May 4th 2023, 5:00pm
Many thoughts went through my mind during cancer, and journaling allowed me to organize them and helped me to feel better.
April 13th 2023, 5:00pm
After being diagnosed with mesothelioma and undergoing a long surgery, I wanted to do it all, but I just couldn’t. Family and friends stepped in to help.
January 4th 2023, 4:00pm
We need to learn more about how to potentially lessen toxins' effects on people's lives.
December 24th 2022, 2:00pm
Imfinzi alone or combined with Imjudo may improve survival and tumor response when administered before surgery, opening the door to neoadjuvant mesothelioma treatments.
What To Know About Having Radiation for Metastatic Prostate Cancer
First Patient Dosed With Annamycin and Cytarabine in Phase 3 AML Trial
Second-Line Tovecimig Elicits Responses in Biliary Tract Cancer
Tagrisso May Improve Survival in Advanced EGFR-Mutant NSCLC